Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

U.S. State Attorneys General Probe Opioid Drug Companies

Nate Raymond  |  

(Reuters)—A bipartisan group of state attorneys general announced on Thursday that they are jointly investigating the marketing and sales practices of drug companies that manufacture opioid painkillers at the center of a national addiction epidemic. Attorneys general from states including Massachusetts, Texas, Illinois and Pennsylvania announced the investigation two weeks after Ohio Attorney General Mike…

Rheumatology Online Educational Courses Among Key ARHP Pillars

Paul M. Adam, MSW, & Afton L. Hassett, PsyD  |  

Editor’s note: The new Pillar Talk column is developed by the ARHP Executive Committee in an effort to share information about ongoing activities related to our four pillars: Education, Practice, Research and Advocacy. The ARHP Online Education Portfolio continues to evolve and grow. The Advanced Rheumatology Course (ARC) and the Fundamentals of Rheumatology Course (FRC)…

Rheumatologists Treating Patients with HIV Face Treatment, Diagnostic Challenges

Rheumatologists Treating Patients with HIV Face Treatment, Diagnostic Challenges

  |  

Rheumatologists treating HIV patients in 2017 must think through many important factors as this population ages. As we continue to learn, rheumatologists must consider important drug–drug interactions, relatively uncommon rheumatological presentations of HIV, as well as specific diagnostic challenges. Working closely with infectious disease specialists is the best way to achieve optimum care for this…

RISE Summit Establishes Priorities, Direction for Registry

  |  

On Feb. 16, ACR leaders, insurers, pharmaceutical representatives, patients, patient advocacy representatives and more met in Scottsdale, Ariz. They came together for the first annual RISE Summit, aimed at setting strategic priorities and goals for the Rheumatology Informatics System for Effectiveness (RISE) Registry, the qualified clinical data registry developed by the ACR. The Rise of…

ACR Works for Global Access to Meeting

  |  

Thousands of attendees travel to the ACR/ARHP Annual Meeting from outside the U.S. to learn, network and exchange ideas. From Nov. 3–8 in San Diego, speakers from more than 30 different countries are scheduled to participate. The ACR is taking action to maintain diverse attendance in a challenging climate for international travel. New traveler vetting and…

The ACR Is Exploring a Rheumatology-Specific APM

  |  

In response to the required changes in reimbursement from fee for service to value-based payment under the Medicare Access and CHIP Reauthorization Act (MACRA) of 2015, the ACR is exploring development of a rheumatology-specific alternative payment model (APM) for rheumatologists and practices, which would provide an additional option for payment other than the Merit-Based Incentive…

Texas Rheumatologists Push for Passage of Step Therapy Reforms

  |  

On May 25, with Gov. Greg Abbott’s signing of Senate Bill 680, Texas became the fourth state this year to increase protection for patients subject to insurers’ step therapy protocols. The State of Texas Association of Rheumatologists (STAR) joined with 35 other professional societies and patient advocacy organizations in urging passage of S.B. 680. The…

More Effective Antifibrotic Therapies for Systemic Sclerosis in Development; Adverse Events A Concern

  |  

Systemic sclerosis (SSc) is a rare disease affecting about 49,000 U.S. adults, and it is strongly associated with high levels of morbidity and mortality.1 Of the few available antifibrotic therapies, none is targeted for SSc. However, reason for optimism exists for antifibrotic treatments in early development and clinical trials, says Jörg H.W. Distler, MD, Heisenberg Professor…